Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Bornem – page 13

2 138 clinical trials in Bornem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bornem at a glance
2 138
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 138 trials in Bornem

Open in trial search

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Asthma

Recruiting

Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:KT-621
  • Sponsor:Kymera Therapeutics Inc.

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Phase 3 Study of Engasertib to Evaluate Safety and Effectiveness in Adults with Moderate to Severe Hereditary Hemorrhagic Telangiectasia

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Engasertib
  • Sponsor:Vaderis Therapeutics AG

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azenosertib
  • Sponsor:K-Group Beta Inc.

Neoplasm

Recruiting

Phase 1/2 Study of ter-2013-01, imlunestrant, and fulvestrant in patients with solid tumors with AKT/PI3K/PTEN pathway alterations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Terremoto Biosciences Inc.

Phase III Randomized Open‑Label Trial of BNT324 vs Docetaxel Plus Prednisone in Patients with Metastatic Castration‑Resistant Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BNT324
  • Sponsor:BioNTech SE

Spironolactone with drug combination to improve health in adults with Fontan circulation (clinical trial)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Dapagliflozin
  • Sponsor:UZ Leuven

Efficacy and Safety of BAY 3670549 in Adults with Atrial Fibrillation: A Randomized, Double‑Blind, Placebo‑Controlled Phase 2 Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BAY 3670549
  • Sponsor:Bayer AG

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Bornem

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colon cancer treatment and survival outcomes. Research explores the potential benefits of common medications in cancer recurrence prevention.

  • Cancer Survival Studies
  • Preventive Medicine
  • Post-Surgery Care

The study examines how acetylsalicylic acid therapy might improve long-term survival rates for patients who have undergone colon cancer surgery, specifically targeting stage II and III cases.

02 Preventive Medicine

Investigation into the role of daily aspirin therapy in preventing cancer recurrence, representing an innovative approach to post-operative care in oncology.

  • Long-term Patient Care
  • Drug Repurposing
  • Cancer Prevention

This research explores how commonly available medications might be repurposed to enhance cancer treatment outcomes and improve patient survival rates.

03 Surgical Oncology

Studies focusing on patients with resected colon carcinoma, examining post-surgical interventions that may enhance treatment success.

  • Post-Operative Care
  • Cancer Recovery
  • Treatment Optimization

Research aimed at developing comprehensive treatment strategies that combine surgical intervention with long-term preventive measures.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.